Annual report [Section 13 and 15(d), not S-K Item 405]

Fair Value Measurements (Narrative) (Details)

v3.26.1
Fair Value Measurements (Narrative) (Details)
$ in Thousands
Dec. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
Jul. 15, 2024
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Common stock warrant liabilities $ 1 $ 214  
Level 3 | Aevitas      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Fair value option and estimated the fair value $ 2,600    
Risk-free interest rate | Level 3      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Retained investment, deconsolidated subsidiary, measurement input 0.0361    
Expected Volatility | Level 3      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Retained investment, deconsolidated subsidiary, measurement input 0.80    
Discount for lack of marketability | Level 3      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Retained investment, deconsolidated subsidiary, measurement input 0.316    
Avenue | Common Stock Warrant      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Common stock warrant liabilities $ 1,000 $ 16,000  
Urica | Crystalys Therapeutics, Inc      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Shares received to maintain ownership Percentage     15.00%
Urica | Crystalys Therapeutics, Inc | Level 3      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Estimated fair value $ 15,100